Mirikizumab: all 44 studies that test it

Page 1 of 1. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.

• MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's DiseaseNot yet recruitingNCT07782021Phase 4
• INSIGHT-IBD Pragmatic StudyEnrolling by invitationNCT07686757Phase 4
• Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed, Moderate-to-severe Crohn's DiseaseNot yet recruitingNCT07659353Phase 4
• A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved IndicationRecruitingNCT07612267Phase 4
• A Study of Mirikizumab Solution (LY3074828) in Healthy ParticipantsRecruitingNCT07446101Phase 1
• Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's DiseaseRecruitingNCT07292012Phase 4
• Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative ColitisRecruitingNCT07235904Phase 4
• Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative ColitisNot yet recruitingNCT07059130Phase 4
• Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CDRecruitingNCT06997965Phase 4
• Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the PouchRecruitingNCT06864403Phase 4
• A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's DiseaseRecruitingNCT05509777Phase 3
• A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)RecruitingNCT04844606Phase 3
• A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy ParticipantsCompletedNCT06475729Phase 1Results posted
• A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT05767021Phase 3Results posted
• A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy ParticipantsCompletedNCT05644353Phase 1Results posted
• A Bioequivalence Study of Mirikizumab (LY3074828) in Healthy ParticipantsCompletedNCT05515601Phase 1Results posted
• A Study to Compare Two Formulations of Mirikizumab (LY3074828) in Healthy ParticipantsCompletedNCT05069896Phase 1Results posted
• A Study of Mirikizumab in Healthy ParticipantsCompletedNCT04607733Phase 1Results posted
• A Study to Compare Two Different Formulations of Mirikizumab in Healthy ParticipantsCompletedNCT04548219Phase 1Results posted
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseActive, not recruitingNCT04232553Phase 3Results posted
• A Study of Mirikizumab in Healthy Chinese ParticipantsCompletedNCT04137380Phase 1Results posted
• A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)CompletedNCT04004611Phase 2Results posted
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseCompletedNCT03926130Phase 3Results posted
• A Study of Mirikizumab in Participants With Plaque PsoriasisCompletedNCT03718884Phase 1Results posted
• A Study of Two Formulations of LY3074828 in Healthy ParticipantsCompletedNCT03662100Phase 1Results posted
• A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)TerminatedNCT03556202Phase 3Results posted
• A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)CompletedNCT03535194Phase 3Results posted
• A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03524092Phase 3Results posted
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)CompletedNCT03518086Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03482011Phase 3Results posted
• A Study of LY3074828 in Healthy ParticipantsCompletedNCT03456713Phase 1Results posted
• A Study of Two Different Formulations of LY3074828 in Healthy ParticipantsCompletedNCT03188510Phase 1Results posted
• A Study of Mirikizumab (LY3074828) Injection in Healthy ParticipantsCompletedNCT03053622Phase 1Results posted
• A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT02899988Phase 2Results posted
• A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's DiseaseCompletedNCT02891226Phase 2Results posted
• A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT02589665Phase 2Results posted
• A Study of Mirikizumab (LY3074828) in Healthy ParticipantsCompletedNCT02568423Phase 1Results posted
• A Safety Study of Mirikizumab (LY3074828)CompletedNCT01947933Phase 1Results posted
• Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic MucosaCompletedNCT06626165Phase 4
• A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative ColitisCompletedNCT05784246Phase 3
• A Study of Mirikizumab (LY3074828) in Participants With Ulcerative ColitisWithdrawnNCT04469062Phase 3
• Study of LY3074828 in Healthy ParticipantsCompletedNCT03748940Phase 1
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)Active, not recruitingNCT03519945Phase 3
• A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy ParticipantsCompletedNCT03220126Phase 1

← Mirikizumab overview